MedTrace Logo

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT05170204 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-05-06

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) NSCLC staging system.

Conditions

Interventions

DRUG

Alectinib

Participants will receive oral alectinib twice daily with food.

DRUG

Entrectinib

Participants will receive oral entrectinib once daily, with or without food.

DRUG

Durvalumab

Participants will receive durvalumab, IV Q4W.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2030-06-16
Completion
2030-06-16
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Chile
  • China
  • Colombia
  • France
  • Germany
  • Italy
  • Japan
  • Mexico
  • Poland
  • Singapore
  • South Korea
  • Sweden
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170204 on ClinicalTrials.gov